药物诱导c-MYB降解靶向治疗急性髓系白血病
研究利用MLL重排急性髓系白血病(AML)的c-MYB基因表达特征检索Connectivity Map数据库,鉴定出甲苯达唑为c-MYB靶向药物。甲苯达唑通过干扰HSP70伴侣系统经蛋白酶体诱导c-MYB降解,短暂暴露即可抑制AML细胞集落形成而不影响正常脐血来源细胞,并在小鼠异种移植实验中有效损害AML进展。
要点
- 甲苯达唑经干扰HSP70伴侣系统、通过蛋白酶体诱导c-MYB降解。
- 短暂暴露甲苯达唑足以抑制AML细胞集落形成,但不抑制正常脐血来源细胞。
- 甲苯达唑在小鼠异种移植实验中有效损害AML进展。
核心结论
- 甲苯达唑诱导的c-MYB降解代表一种安全的新型AML治疗策略。
研究设计与样本
- 利用MLL重排AML的c-MYB基因表达特征检索Connectivity Map数据库,鉴定c-MYB靶向药物。
- 在AML细胞和正常脐血来源细胞中检测甲苯达唑对集落形成的影响。
- 在小鼠异种移植实验中检测甲苯达唑对AML进展的影响。
主要发现
- 甲苯达唑通过干扰热休克蛋白70(HSP70)伴侣系统、经蛋白酶体诱导c-MYB降解。
- 短暂暴露于甲苯达唑足以抑制AML细胞集落形成,但不抑制正常脐血来源细胞。
- 甲苯达唑在小鼠异种移植实验中有效损害AML进展。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite advances in our understanding of the molecular basis for particular subtypes of acute myeloid leukemia (AML), effective therapy remains a challenge for many individuals suffering from this disease. A significant proportion of both pediatric and adult AML patients cannot be cured and since the upper limits of chemotherapy intensification have been reached, there is an urgent need for novel therapeutic approaches. The transcription factor c-MYB has been shown to play a central role in the development and progression of AML driven by several different oncogenes, including mixed lineage leukemia (MLL)-fusion genes. Here, we have used a c-MYB gene expression signature from MLL-rearranged AML to probe the Connectivity Map database and identified mebendazole as a c-MYB targeting drug. Mebendazole induces c-MYB degradation via the proteasome by interfering with the heat shock protein 70 (HSP70) chaperone system. Transient exposure to mebendazole is sufficient to inhibit colony formation by AML cells, but not normal cord blood-derived cells. Furthermore, mebendazole is effective at impairing AML progression in vivo in mouse xenotransplantation experiments. In the context of widespread human use of mebendazole, our data indicate that mebendazole-induced c-MYB degradation represents a safe and novel therapeutic approach for AML.
引用
- Walf-Vorderwülbecke V, Pearce K, Brooks T, et al. Targeting acute myeloid leukemia by drug-induced c-MYB degradation. Leukemia. 2017. PMID: 29089643. doi:10.1038/leu.2017.317
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。